MARKET

XENT

XENT

Intersect ENT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.69
+1.80
+9.05%
After Hours: 21.69 0 0.00% 16:04 12/03 EST
OPEN
20.00
PREV CLOSE
19.89
HIGH
21.75
LOW
19.91
VOLUME
377.44K
TURNOVER
--
52 WEEK HIGH
31.46
52 WEEK LOW
5.97
MARKET CAP
709.68M
P/E (TTM)
-11.7104
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Intersect ENT (XENT) Up 17.6% Since Last Earnings Report: Can It Continue?
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 1d ago
Intersect ENT Announces New Appointments to Executive Leadership Team
Intersect ENT Announces New Appointments to Executive Leadership Team
Business Wire · 11/17 21:45
Intersect ENT Announces New Appointments to Executive Leadership Team
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today announced the appointments of Patrick Broderick as Executive Vice President, General Counsel (GC) and Corporate Secretary, and Reyna Fernandez as Chief Human Resource Officer (CHRO). Both Mr. Broderick and Ms. Fernandez will begin serving their new roles on November 30, 2020, reporting to Tom West, President and CEO of Intersect ENT.
BusinessWire · 11/17 18:45
The Experience Design Studio Adds Key New Clients to its Roster
The Experience Design Studio (XDS), a digitally native, full-service customer experience agency, announced today a surge in growth adding several new clients to its expanding roster and substantially growing relationships with a slew of existing clients. XDS, which was recognized this year by both W3 and Davey with multiple awards, has been brought on to strengthen each company's online positioning, digital marketing, social media presence, and overall branding. These client wins have been added to XDS's current array of existing clients, which span across the biggest names in healthcare.
BusinessWire · 11/11 10:00
Intersect ENT to Participate at Upcoming Investor Conferences
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat ("ENT") conditions, today announced that management will participate in the following upcoming investor conferences:
BusinessWire · 11/05 18:05
Intersect ENT Reports Third Quarter 2020 Financial Results
Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat ("ENT") conditions, today reported financial results for the third quarter ended September 30, 2020.
BusinessWire · 11/02 09:00
Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View
Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.
Zacks · 10/20 14:27
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15)
Benzinga · 10/16 11:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XENT. Analyze the recent business situations of Intersect ENT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XENT stock price target is 20.13 with a high estimate of 32.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 196
Institutional Holdings: 40.36M
% Owned: 123.34%
Shares Outstanding: 32.72M
TypeInstitutionsShares
Increased
34
3.65M
New
29
-14.11K
Decreased
43
3.12M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.85%
Healthcare Equipment & Supplies
-1.15%
Key Executives
Non-Executive Chairman
Kieran Gallahue
President/Chief Executive Officer/Director
Thomas West
Chief Financial Officer/Executive Vice President
Richard Meier
Chief Operating Officer/Executive Vice President
Christine Kowalski
Chief Human Resource Officer
Gwen Carscadden
Chief Human Resource Officer
Reyna Fernandez
Executive Vice President/General Counsel/Secretary
Patrick Broderick
Independent Director
Teresa Kline
Independent Director
Cynthia Lucchese
Independent Director
Dana Mead
Independent Director
Frederic Moll
Independent Director
William Vernon
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About XENT
Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Intersect ENT Inc stock information, including NASDAQ:XENT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XENT stock methods without spending real money on the virtual paper trading platform.